×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Leap Therapeutics Announces $40 Million Private Placement
PR Newswire
PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology...
1 month ago
Leap Therapeutics Reports First Quarter 2024 Financial Results
Yahoo Finance
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics,...
1 week ago
LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023
MSN
LPTX stock results show that Leap Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.More From InvestorPlace The #1 AI...
3 days ago
HC Wainwright Trims Leap Therapeutics (NASDAQ:LPTX) Target Price to $5.50
Defense World
Read HC Wainwright Trims Leap Therapeutics (NASDAQ:LPTX) Target Price to $5.50 at Defense World.
5 days ago
Leap Therapeutics Shares Rise 9% After Pricing of Private Placement
MarketWatch
By Chris Wack Leap Therapeutics shares were rose after the company entered a securities purchase agreement with a group of institutional...
1 month ago
Leap Therapeutics: The DisTinGuish Trial Provides A Near-Term Catalyst
Seeking Alpha
Leap Therapeutics is developing DKN-01, a drug with potential in multiple types of cancer. Read my earnings analysis of LPTX stock here.
1 week ago
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
Yahoo Finance
Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
2 months ago
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal ...
PR Newswire
The DeFianCe study (NCT05480306) is a Phase 2, open-label, global study of DKN-01 in combination with standard of care bevacizumab and...
4 months ago
Leap Therapeutics (NASDAQ:LPTX) Will Have To Spend Its Cash Wisely
Yahoo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
1 day ago
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of ...
PR Newswire
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of...
4 months ago